Affimed to Present at the 2022 Jefferies London Healthcare Conference
November 01 2022 - 6:30AM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, announced today that its
Chief Executive Officer, Dr. Adi Hoess, will present at the 2022
Jefferies London Healthcare Conference on Wednesday, November 16,
2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.
A live webcast of the presentation will be
accessible on Affimed’s website at
https://www.affimed.com/investors/webcasts-and-corporate-presentation/.
A replay of the call will be archived on Affimed’s website for 30
days after the call.
For more information on the conference or to
schedule a one-on-one meeting with Affimed management, please
contact your Jefferies representative or Alex Fudukidis via email
at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.
About Affimed N.V.Affimed
(Nasdaq: AFMD) is a clinical-stage immuno-oncology company
committed to give patients back their innate ability to fight
cancer by actualizing the untapped potential of the innate immune
system. The Company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs.The ROCK® platform predictably generates customized innate
cell engager (ICE®) molecules, which use patients’ immune cells to
destroy tumor cells. This innovative approach enabled Affimed to
become the first company with a clinical-stage ICE®. Headquartered
in Heidelberg, Germany, with offices in New York, NY, Affimed is
led by an experienced team of biotechnology and pharmaceutical
leaders united by a bold vision to stop cancer from ever derailing
patients’ lives. For more about the Company’s people, pipeline and
partners, please visit: www.affimed.com.
Affimed Investor ContactAlexander
FudukidisDirector, Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024